[Source: JAMA, full page: (LINK). Summary, edited.]
Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020
Neeraj Sood, PhD1; Paul Simon, MD2; Peggy Ebner, BA3; et al. Daniel Eichner, PhD4; Jeffrey Reynolds, MA5; Eran Bendavid, MD6; Jay Bhattacharya, MD, PhD6
Author Affiliations: 1 Schaeffer Center for Health Policy and Economics, Sol Price School of Public Policy, University of Southern California, Los Angeles; 2 Los Angeles County Department of Public Health, Los Angeles, California; 3 Keck School of Medicine, University of Southern California, Los Angeles; 4 Sports Medicine Research and Testing Laboratory, Salt Lake City, Utah; 5 LRW Group, Los Angeles, California; 6 Stanford University School of Medicine, Palo Alto, California
JAMA. Published online May 18, 2020. doi:10.1001/jama.2020.8279
Inadequate knowledge about the extent of the coronavirus disease 2019 (COVID-19) epidemic challenges public health response and planning. Most reports of confirmed cases rely on polymerase chain reaction–based testing of symptomatic patients.1 These estimates of confirmed cases miss individuals who have recovered from infection, with mild or no symptoms, and individuals with symptoms who have not been tested due to limited availability of tests. We conducted serologic tests in a community sample to estimate cumulative incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as serologic tests identify both active and past infections.
Keywords: SARS-CoV-2; COVID-19; Serology; Seroprevalence; California; USA.